Alecensa: payments to doctors
Payments that named Alecensa as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.6M
- Providers
- 5,133
- Transactions
- 14,503
- Average per transaction
- $114
The per-transaction average — $114 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,133 providers the average total is $321, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech USA, Inc. | $1,303,104 | 79.0% |
| F. Hoffmann-la Roche AG | $219,841 | 13.3% |
| Genentech, Inc. | $79,664 | 4.8% |
| Hoffmann-la Roche Limited | $24,783 | 1.5% |
| Roche Products Limited | $18,843 | 1.1% |
| Chugai Pharmaceutical Co., Ltd. | $3,300 | 0.2% |